Pfizer and BioNTech’s COVID-19 Vaccines Training Resources for All Healthcare Providers led by Pfizer Vaccines US Medical Affairs

Session Topics Include:

• Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) to provide a single booster dose at least 2 months after completion of primary vaccination with 3 doses of Pfizer-BioNTech COVID-19 Vaccine [monovalent] for individuals 6 months through 4 years of age (Maroon Cap)
• Use of currently authorized vaccines, including storage, handling, preparation, and administration
• Question and answer session

Continuing medical education is NOT associated with this content

Emergency uses of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or   
licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease (COVID-19) in individuals aged 6 months and older as appropriate. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of
the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Before administration, please see full Prescribing Information: 12 years of age and older or appropriate EUA Fact Sheet for Vaccination Providers.  For the most recent prescribing information and fact sheets, please visit www.cvdvaccine-us.com